Correlation analysis of clinical parameters with epigenetic modifications in the DUX4 promoter in FSHD

Epigenetics

Volumn 7, Issue 6, 2012, Pages 579-584

  Balog, Judit ^a   Thijssen, Peter E ^a   de Greef, Jessica C ^a   Shah, Bharati ^b   van Engelen, Baziel G M ^c   Yokomori, Kyoko ^d   Tapscott, Stephen J ^e   Tawil, Rabi ^b   van der Maarel, Silvère M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Chromatin compaction score; Chromatin immunoprecipitation; Clinical severity score; D4Z4; DUX4; FSHD; Histone modifications; Muscle pathology score

Indexed keywords

AGE; ARTICLE; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DOUBLE HOMEOBOX GENE 4; EPIGENETICS; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 2; FEMALE; FIBROBLAST; GENE; HISTONE 3 LYSINE 4 DIMETHYLATION; HISTONE 3 LYSINE 9 TRIMETHYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MUSCLE DISEASE; MYOBLAST; PROMOTER REGION; VASTUS LATERALIS MUSCLE;

EID: 84861934838     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.20001     Document Type: Article

References (15)

1. Padberg GW. Facioscapulohumeral disease. Leiden University, Leiden 1982.
2. de Greef JC, Lemmers RJ, Camaño P, Day JW, Sacconi S, Dunand M, et al. Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology 2010; 75:1548-54; PMID:20975055; http://dx.doi.org/10.1212/WNL.0b013e3181f96175.
3. van Overveld PG, Lemmers RJ, Sandkuijl LA, Enthoven L, Winokur ST, Bakels F, et al. Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat Genet 2003; 35:315-7; PMID:14634647; http://dx.doi.org/10.1038/ng1262.
4. Zeng W, de Greef JC, Chen YY, Chien R, Kong X, Gregson HC, et al. Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). PLoS Genet 2009; 5:1000559; PMID:19593370; http://dx.doi.org/10.1371/journal.pgen.1000559.
5. de Greef JC, Lemmers RJ, van Engelen BG, Sacconi S, Venance SL, Frants RR, et al. Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Hum Mutat 2009; 30:1449-59; PMID:19728363; http://dx.doi.org/10.1002/humu.21091.
6. Snider L, Asawachaicharn A, Tyler AE, Geng LN, Petek LM, Maves L, et al. RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy. Hum Mol Genet 2009; 18:2414-30; PMID:19359275; http://dx.doi.org/10.1093/hmg/ddp180.
7. Tawil R, Forrester J, Griggs RC, Mendell J, Kissel J, McDermott M, et al.; The FSH-DY Group. Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. Ann Neurol 1996; 39:744-8; PMID:8651646; http://dx.doi.org/10.1002/ana.410390610.
8. Lunt PW, Jardine PE, Koch MC, Maynard J, Osborn M, Williams M, et al. Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD). Hum Mol Genet 1995; 4:951-8; PMID:7633457; http://dx.doi.org/10.1093/hmg/4.5.951.
9. Ricci E, Galluzzi G, Deidda G, Cacurri S, Colantoni L, Merico B, et al. Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype. Ann Neurol 1999; 45:751-7; PMID:10360767; http://dx.doi.org/10.1002/1531-8249(199906)45:6751::AIDANA93.0.CO;2-M.
10. van Overveld PG, Enthoven L, Ricci E, Rossi M, Felicetti L, Jeanpierre M, et al. Variable hypomethylation of D4Z4 in facioscapulohumeral muscular dystrophy. Ann Neurol 2005; 58:569-76; PMID:16178028; http://dx.doi.org/10.1002/ana.20625.
11. Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, Epstein CB, et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 2011; 473:43-9; PMID:21441907; http://dx.doi.org/10.1038/nature09906.
12. Tonini MM, Passos-Bueno MR, Cerqueira A, Matioli SR, Pavanello R, Zatz M. Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD). Neuromuscul Disord 2004; 14:33-8; PMID:14659410; http://dx.doi.org/10.1016/j.nmd.2003.07.001.
13. Frisullo G, Frusciante R, Nociti V, Tasca G, Renna R, Iorio R, et al. CD8(+) T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI. J Clin Immunol 2011; 31:155-66; PMID:21063901; http://dx.doi.org/10.1007/s10875-010-9474-6.
14. Lemmers RJ, van der Wielen MJ, Bakker E, Frants RR, van der Maarel SM. Rapid and accurate diagnosis of facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2006; 16:615-7; PMID:16938455; http://dx.doi.org/10.1016/j.nmd.2006.07.013.
15. Nelson JD, Denisenko O, Bomsztyk K. Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat Protoc 2006; 1:179-85; PMID:17406230; http://dx.doi.org/10.1038/nprot.2006.27.